MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

AM095

CAS No. : 1345614-59-6

MCE 国际站：AM095

产品活性：AM095 是一种选择性的 LPA₁ 受体拮抗剂。作用于人和鼠 转染 LPA₁ 的 CHO 细胞，AM095 拮抗 LPA 诱导的钙流动，IC₅₀ 分别为 0.025 和 0.023 μM。

研究领域：GPCR/G Protein

作用靶点：LPL Receptor

In Vitro: AM095 is a potent LPA₁ receptor antagonist because it inhibits GTPγS binding to Chinese hamster ovary (CHO) cell membranes overexpressing recombinant human or mouse LPA₁ with IC₅₀ values of 0.98 and 0.73 μM, respectively. AM095 inhibits LPA-driven chemotaxis of CHO cells overexpressing mouse LPA₁ (IC₅₀=778 nM) and human A2058 melanoma cells (IC₅₀=233 nM). The IC₅₀ of AM095 in the human LPA₁ GTPγS binding assay is comparable with that of our previously published compound AM966 (IC₅₀=0.98±0.17 μM) and the Debio-0719 compound (IC₅₀=0.60±0.04 μM). AM095 inhibits the LPA-induced calcium flux of CHO cells stably transfected with human or mouse LPA₁. The IC₅₀ for AM095 antagonism of LPA-induced calcium flux of human or mouse LPA₁-transfected CHO cells is 0.025 and 0.023 μM, respectively.

In Vivo: AM095 has high oral bioavailability and a moderate half-life and is well tolerated at the doses tested in rats and dogs after oral and intravenous dosing. After oral (10 mg/kg) dosing in rats, AM095 plasma concentrations peaked at 2 h with a C_max of 41 μM, thereafter decreasing to 10 nM by 24 h. After intravenous (2 mg/kg) dosing, a C_max of 12 μM is observed within 15 min, which also decreased to approximately 10 nM by 24 h, yielding a t_1/2 of 1.79 h. In dogs, a single oral dose of 5 mg/kg yielded a peak plasma concentration of 21 μM within 15 min of dosing, which then decreased to 10 nM by 24 h. In contrast, an intravenous dose of 2 mg/kg resulted in a C_max of 11 μM within 15 min and decreased to 15 nM by 8 h, yielding a t_1/2 of 1.5 h.

相关产品：Bioactive Compound Library Plus  |  GPCR/G Protein Compound Library  |  Immunology/Inflammation Compound Library  |  Anti-Pulmonary Fibrosis Compound Library  |  Membrane Protein-targeted Compound Library  |  Membrane Receptor-targeted Compound Library  |  Highly Selective Inhibitors Library  |  BMS-986020 sodium  |  ONO-0300302  |  BMS-986278  |  NAEPA  |  Sphingosine-1-phosphate-d₇  |  S1P1 agonist III  |  S1PR1 modulator 1  |  LPA2 antagonist 2  |  Radioprotectin-1  |  S1PR1 agonist 1  |  TC-SP 14  |  CYM50358  |  W146  |  Udifitimod  |  CRT0273750  |  Ki16425  |  ONO-9780307  |  CS-2100  |  Fingolimod phosphate-d₄  |  CAY10444  |  ONO-0740556  |  NIBR0213  |  CYM50260  |  ASP-4058  |  FTY720 (S)-Phosphate  |  Sonepcizumab  |  TAK-615  |  GSK2018682  |  Mocravimod hydrochloride

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物  |  寡核苷酸  |  抗体  |  点击化学

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides  |  Antibodies  |  Click Chemistry

货号: HY-16039

品牌介绍:
•   MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；
•   50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领；
•   产品种类涵盖各种重组蛋白，多肽，常用试剂盒 ，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；
•   提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
•   专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。